Global Protein Therapeutics Market 2016-2020

Global Protein Therapeutics Market 2016-2020

Category : Pharmaceuticals
Published On : November  2015
Pages : 130

------------ Or -------------
 Market outlook of the protein therapeutics market

Technavios market research analyst predicts the global protein therapeutics market to grow steadily at a CAGR of 8% during the forecast period. Increased demand for and use of monoclonal antibodies is expected to drive the growth of the protein therapeutics market as it accounts for more than half of the protein therapeutics market. The monoclonal antibodies can be prepared specific to any cell surface or extracellular target. These antibodies are being used in radioimmunotherapy and antibody-directed enzyme prodrug therapy. Monoclonal antibodies are also used in the formulation of various biopharmaceutical drugs for the treatment of different diseases such as cancer, rheumatoid arthritis, multiple sclerosis, and UC.

The availability of favorable reimbursement policies in this market is expected to boost the market growth during the forecast period. Protein therapeutics are expensive and cannot be afforded by all, but reimbursement of the diagnostic kits and biologic drugs are expected to fuel the market during the forecast period. Plans like the public reimbursement programs reduce the financial burden of treatments. The reimbursement status of drugs varies from region to region, with factors such as lack of cost-effectiveness impeding the coverage.

Product segmentation and analysis of the protein therapeutics market

Monoclonal antibodies
	Human growth hormone
	Blood clotting factor
	Follicle stimulating hormone
The monoclonal antibodies segment dominated the market during 2015, with a market share of 55%. An increase in the prevalence of cancer and autoimmune diseases, increase in research activities, and increased technological advancement in the development of next-generation antibodies are the main factors fueling the growth of this segment.

Geographical segmentation and analysis of the protein therapeutics market

The Americas accounted for 48% of the market share during 2015 and is expected to grow at a CAGR of 7% during the forecast period. The promising public health approaches by the government, growing incidence, and an increase in regulatory support for the development of protein therapeutics are the primary drivers for the market growth in this region.

Competitive landscape and key vendors

The global protein therapeutics market is highly fragmented due to the presence of numerous small and large vendors. The vendors in the market compete on the basis of price, quality, and innovation. Competition among the vendors has led an increased number of M&A, wherein smaller entities are being acquired by, or are being merged with, major players.

The leading vendors in the market are -

	F. Hoffmann-La Roche
	Johnson & Johnson
	Novo Nordisk
Other prominent vendors in the market include Anhui Anke Biotechnology, AstraZeneca, Baxter International, Biocon, Biodel, Biogenomics, BioPartners, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Chugai Pharmaceutical, Diamyd Medical, Diasome Pharmaceuticals, DiaVacs, Dynavax Technologies, Eli Lilly, Ferring Pharmaceuticals, Generex Biotechnology, GeneScience Pharmaceuticals, Hualan Biological Engineering, Intas Pharmaceuticals, Ipsen, JCR Pharmaceuticals, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, LG Life Sciences, Macrogenics, MannKind, Oramed Pharmaceuticals, Osiris Therapeutics, Pfizer, Sandoz International, Sanofi, Teva Pharmaceutical Industries, Thermalin Diabetes, Tolerion, Wockhardt, and XOMA.

Key questions answered in the report include

What will the market size and the growth rate be in 2020
	What are the key factors driving the global protein therapeutics market
	What are the key market trends impacting the growth of the protein therapeutics market
	What are the challenges to market growth
	Who are the key vendors in this market space
	What are the market opportunities and threats faced by the vendors in the global protein therapeutics market
	Trending factors influencing the market shares of the Americas, APAC, and EMEA
	What are the key outcomes of the five forces analysis of the protein therapeutics market
Technavio also offers customization on reports based on specific client requirement.
Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

Market overview
Top-vendor offerings
PART 03: Market research methodology

Research methodology
Economic indicators
PART 04: Introduction

Key market highlights
PART 05: Market landscape

Market overview
Market size and forecast
Five forces analysis
PART 06: Market segmentation by product type

PART 07: Global monoclonal antibody drugs market

Market overview
Market drivers
Market challenges
Market trends
Vendors of global monoclonal antibody drugs market
PART 08: Global insulin market

Market overview
Market drivers
Market challenges
Market trends
Insulin market in Europe
Vendors of global insulin market
PART 09: Global erythropoietin market

Market overview
Market drivers
Market challenges
Market trends
Erythropoietin market in Japan
Vendors of global erythropoietin market
PART 10: Global human growth hormone market

Market overview
Market drivers
Market challenges
Market trends
Vendors of global human growth hormone market
PART 11: Market segmentation by therapy area

Metabolic and endocrine disorders
Autoimmune diseases
Infectious diseases
Protein vaccine
PART 12: Market segmentation by protein function

Enzymatic and regulatory activity
Special targeting activity
Protein diagnostics
PART 13: Geographical segmentation

Global protein therapeutics market by geographical segmentation 2015-2020
Protein therapeutics market in Americas
Protein therapeutics market in EMEA
Protein therapeutics market in APAC
PART 14: Market drivers

Increased demand for monoclonal antibodies
Availability of favorable reimbursement policies
Increasing prevalence of chronic diseases
Promising drug pipeline
Frequent innovations
PART 15: Impact of drivers

PART 16: Market challenges

Patent expiration of top-selling drugs
Stringent regulations
High cost of therapy
Fierce market competition
Risk of side effects
PART 17: Impact of drivers and challenges

PART 18: Market trends

Patient assistance programs
Strategic alliances
Emergence of targeted therapies
Shifting focus toward untapped markets
Increase in public awareness
PART 19: Vendor landscape

Competitive scenario
Market share analysis 2015
Other prominent vendors
PART 20: Key vendor analysis

F.Hoffmann-La Roche
Johnson & Johnson
Merck Serono
Novo Nordisk
PART 21: Appendix

List of abbreviations
PART 22: Explore Technavio

Enquiry Before Buy